Election of Vicente Anido, Jr. to Nicox’s Board of Directors – Vaughn Kailian re-elected Director
June 20, 2013
June 21, 2013.
Sophia Antipolis, France.
Nicox S.A. (NYSE Euronext Paris: COX) today announced the election of Vicente Anido, Jr., PhD., to the Company’s Board of Directors for a period of four years. Dr. Anido is a highly experienced and respected leader in the ophthalmology sector and most recently served as President and Chief Executive Officer of ISTA Pharmaceuticals prior to its acquisition by Bausch + Lomb.
The Company also announced that Vaughn Kailian, Managing Director at MPM Capital and former President & CEO of COR Therapeutics, has been re-elected as a member of the Board of Directors for a period of four years. Bengt Samuelsson and Jorgen Buus Lassen have retired from the Board due to their reaching the age limit set out in the Company’s by-laws.
“I am honoured to join Nicox’s Board of Directors. The Company already has a number of promising assets and a sound strategy to become an international and innovative ophthalmic company. I look forward to sharing my experience and contributing to the future growth of the business”, said Vicente Anido.
“We are pleased to welcome Vicente Anido as a member of the Nicox Board of Directors and would also like to thank Vaughn Kailian for his continued support for Nicox as a Board member” said Michele Garufi, Chief Executive Officer of Nicox. “We look forward to their unique contributions as we continue to transform Nicox into a leading international ophthalmology company.”
“On behalf of the Board, Nicox’s management and its employees I would like to express my sincere gratitude to Bengt Samuelsson and Jorgen Buus Lassen. Their guidance and support has been of great value to the Company over the past fifteen years, particularly during our current period of transition.”